According to Haiwang Biotech's announcement, the cumulative closing price deviation value of the company's stock exceeded 20% for 3 consecutive trading days from December 3 to 5, 2025, and the cumulative increase deviation value exceeded 100% for 8 consecutive trading days from November 26 to December 5, which was a serious abnormal fluctuation. After self-inspection, there was no material information that should be disclosed, and the controlling shareholders, etc. did not trade the company's shares during this period. 2024 revenue of 30.317 billion yuan, net profit - 1,193 billion yuan; revenue of 21,513 billion yuan and net profit of 25.703 million yuan for the first three quarters of 2025. The current net market ratio is 7.64 times, which is different from peers. Investors are reminded to pay attention to risks.

According to Haiwang Biotech's announcement, the cumulative closing price deviation value of the company's stock exceeded 20% for 3 consecutive trading days from December 3 to 5, 2025, and the cumulative increase deviation value exceeded 100% for 8 consecutive trading days from November 26 to December 5, which was a serious abnormal fluctuation. After self-inspection, there was no material information that should be disclosed, and the controlling shareholders, etc. did not trade the company's shares during this period. 2024 revenue of 30.317 billion yuan, net profit - 1,193 billion yuan; revenue of 21,513 billion yuan and net profit of 25.703 million yuan for the first three quarters of 2025. The current net market ratio is 7.64 times, which is different from peers. Investors are reminded to pay attention to risks.